Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Diabetes, Obesity & Metabolism|March 12, 2026
Cardio-Kidney-Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney DiseaseM Luiza Caramori, Enrico Repetto, Christopher Perkins, et al.
Diabetes Care|October 30, 2025
Screening Natriuretic Peptide Levels Predicts Heart Failure and Death in Individuals With Type 1 and Type 2 Diabetes Without Known Heart FailureRodica Pop-Busui, Enrico Repetto, Jason Baron, et al.
Diabetes, Obesity & Metabolism|November 7, 2019
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetesAmalia Gastaldelli, Enrico Repetto, Cristian Guja, et al.
Frontiers in Aging Neuroscience|October 17, 2017
The Decrease of Uch-L1 Activity Is a Common Mechanism Responsible for Aβ 42 Accumulation in Alzheimer's and Vascular DiseaseMichela Guglielmotto, Debora Monteleone, Valeria Vasciaveo, et al.
The American Journal of Managed Care|January 3, 2024
Cost analysis of self-monitoring blood glucose in nonintensively managed type 2 diabetesDavid Kerr, Ian Duncan, Enrico Repetto, et al.
Journal of Alzheimer'S Disease : JAD|August 28, 2019
Stroke and Amyloid-β Downregulate TREM-2 and Uch-L1 Expression that Synergistically Promote the Inflammatory ResponseMichela Guglielmotto, Ivan Enrico Repetto, Debora Monteleone, et al.
Diabetes, Obesity & Metabolism|September 12, 2024
Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysisSatish K Garg, Irl B Hirsch, Enrico Repetto, et al.
JAMA Network Open|October 31, 2025
Continuous Glucose Monitoring Frequency and Glycemic Control in People With Type 2 DiabetesIrl B Hirsch, Satish K Garg, Enrico Repetto, et al.
Diabetes, Obesity & Metabolism|August 31, 2019
Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 studyEle Ferrannini, Simona Baldi, Juan P Frías, et al.
Annals of the New York Academy of Sciences|July 13, 2002
Hormone replacement therapy and chronic graft-versus-host disease activity in women treated with bone marrow transplantation for hematologic malignanciesEnrico Balleari, Simona Garre, Maria Teresa Van Lint, et al.
Pageof 2